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Background: The aetiology of colorectal cancer (CRC) remains elusive in the majority of cases. There is
experimental evidence to show that HMG-CoA reductase inhibitors (statins) may inhibit proliferation and induce
cause apoptosis in CRC cells and although some clinical studies have suggested that statins may protect against the
development of CRC, this has not been a consistent finding. Therefore we have examined any potential protective
effects of statins by comparing statin use in patients with colorectal cancer against a control group.
Methods: This was a case–control study examining statin use in symptomatic patients attending for diagnostic
colonoscopy. Statin use was compared between patients with CRC and a control group, who had all had normal
colonoscopy. Structured interviews and clinical records notes were used to determine drug exposure. Logistic
regression was used to compare statin exposure and correct for confounding factors.
Results: There was a significant inverse association between previous statin use and a diagnosis of CRC (OR = 0.43
(95% confidence interval 0.25 – 0.80), p< 0.01). This inverse association was stronger with higher statin doses
(OR = 0.19 (0.07 – 0.47), p< 0.01) and greater duration of statin use (statin use >5 years: OR = 0.18 (0.06 – 0.55),
p< 0.01).
Conclusions: Statins use was associated with a protective effect against the development of CRC. This effect is
associated with a significant dose and duration response. These findings need to be repeated in other observational
studies before an interventional study can be considered.
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Colorectal cancer (CRC) is common, with an incidence of
20.1/100,000/year in men and 14.6/100,000/year in women
[1]. Worldwide, the incidence of CRC ranks fourth in
frequency in men and third in women. CRC accounts for
over 1 million new cases of cancer each year, 9.4% of the
world’s total [2]. The prevalence is second only to that of
breast cancer worldwide, with an estimated 2.8 million
people alive with bowel cancer within 5 years of diagnosis
[1,2]. The disease causes over 592,000 deaths each year [1].
Treatment involves surgical resection of the bowel in over
80% of patients. Adjuvant chemotherapy may reduce local* Correspondence: i.beales@uea.ac.uk
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reproduction in any medium, provided the orirecurrence and mortality but is dependent on the stage of
the cancer. Fewer than 50% of patients survive more than
5 years after diagnosis [1,3]. Although improved surgical
and oncological techniques and population-wide screening
programmes have certainly had a positive impact on the
incidence and outcomes from CRC, further benefits in
outcomes should be possible with chemopreventative
strategies. At present there are no widely accepted chemo-
preventative interventions. Inhibition of cyclooxygenase-2
(COX-2) has been associated with a reduced incidence of
CRC in case control studies and experimental animal
studies have given encouraging results [4]. However
although COX-2 inhibitors do reduce adenomatous polyp
formation, the adverse cardiovascular profile of these
drugs, will undoubtably prevent their use in a wide
chemopreventative strategy [5]. The potential fortral Ltd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
ginal work is properly cited.
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tion strategy, especially as many of the risk factors such as
obesity and hyperinsulinaemia are common to both
vascular disease and CRC [6]. Although long-term use of
aspirin does seem to reduce the incidence of CRC, it is not
currently recommended because of the increased risk of
bleeding [7].
Against this background, the effects of HMG-CoA
reductase inhibitors (statins) are particularly pertinent.
On one hand they could be expected to be commonly
prescribed to patients at risk of colon cancer, hence
any effects on increasing CRC risk may be clinically
important and on the other, there are data suggesting a
potentially important protective effect of statins against
CRC [8-12]. Laboratory studies have shown that
statins induce apoptosis, inhibit proliferation and
reduce invasion in multiple colon cancer cell lines
[13,14]. This effect seems to be a class effect and has
been documented with lovastatin, simvastatin, prava-
statin and atorvastatin and is most plausibly due to the
inhibition of the mevalonate synthetic pathway reducing
the cellular availability of substrates required for the
isoprenylation of small signaling G-proteins and the
resultant inhibition of pro-carcinogenic and pro-survival
pathways [13-15]. Other protective mechanisms have
been suggested, including anti-inflammatory actions,
reduction in circulating lipids and a beneficial effect on
adipokine secretion profiles [16].
Clinical studies with statins and CRC have given
variable results. Two separate studies showed a highly
significant 50% reduction in CRC incidence in statin
users [8,11]. A more recent observational study showed
a 38% reduction in CRC incidence only in lovastatin
users with a non-significant trend for greater protection
with more than 3 years therapy [17] and two separate
meta-analyses suggested a protective effect of statins
[9,18] Bardou at al confirmed that randomized
controlled trials tended to show a small a non-significant-
reduction in CRC incidence in statin users, whilst
observational and case–control studies suggested a
persistent but modest protective effect of statins [18].
These differences are thought to arise from the low
absolute incidence of CRC in the randomized trials and
relatively limited short term nature of statin trials, which
were not primarily designed to examine cancer incidence.
In addition to lovastatin protective effects have been
reported with simvastatin and pravastatin [8,19]. However
other studies, often with different methodologies have
shown no effects [19-25]. The reasons for these discrepan-
cies are not clear but probably involve differences in the
study design, populations, specific statin use in different
populations, age at initiation of statin use and the controls
examined, duration of statin exposure and exposure to
confounding factors. However, many of the recentobservational studies had significant limitations with statin
use being measured from prescriptions and an uninvesti-
gated control group recruited from general practice data-
bases. In several of the studies statin exposure was
regarded as positive if as little as one prescription or
3 months therapy was taken [24,25]. The maximal dur-
ation of follow up in cohort studies was usually less than
5 years and this may not have been sufficient time for the
effects of statins to become apparent as other studies with
over 5 years, or a mean of 9 years follow up showed more
protective effects [8,10]. A recent longer-term study
showed that> 5 years statin exposure, assessed using a
questionnaire, was not associated with a reduced incidence
of colon cancer [26]. Statins and other medications pur-
chased over the counter were not included in many of the
studies and neither BMI nor smoking data were available
in all studies. The controls were not investigated with en-
doscopy so there was no certainty over these diagnoses
and no information available to assess early CRC. One
major review confirmed that the data on statins and colon
cancer were conflicting and inconsistent and although a
number of studies have provided no evidence of protec-
tion, the situation was sufficiently unclear that further clin-
ical studies were warranted [19].
Therefore, given this uncertainty we have examined
the effect of statin use on the incidence of CRC in an
average risk United Kingdom population.
Methods
Study design
This study was conducted as a retrospective case–
control study. Information was obtained from brief
structured patient interviews and was verified through
subsequent review of the clinical notes and past referral
letters. Where there was incongruence between prescrip-
tions indicated in the clinical notes and that relayed by
the patients, the patients’ answer was taken as the most
accurate description of drugs being taken. A history of
the patient’s statin use was gathered, including the dose,
duration and type of statin that was used. Statin use in
the 6 months prior to diagnosis was excluded because
the potential chemopreventative effects of statins
may not have materialized after such short term use.
Information regarding exposure to other known risk
factors was also collected using the standardized interview.
Regular use of aspirin or NSAIDs was defined as one dose
per week or more. The interviews lasted 15 minutes and
were conducted in a private interview room.
Study population
All the patients were under the care of the Gastroenter-
ology Department at the Norfolk and Norwich Univer-
sity Hospital. This is a large University Teaching
Hospital serving a predominantly rural population of
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sistent referral patterns within the catchment population
has been noted in previous epidemiological studies [27]
and drug histories could almost always be verified by
clinical notes.
Controls
Patients attending for their first diagnostic colonoscopy
from 1/09/2009 to 31/5/2010 were invited to participate.
Patients having a colonoscopy for surveillance for
inflammatory bowel disease or previous adenomatous
polyps or cancer were excluded as were those where the
indication was a screening colonoscopy in asymptomatic
patients for a high risk family history, acromegaly or
previous uretosigmoidostomy. All patients were aged
over 18, fluent in spoken English and underwent a
structured interview prior to having a diagnostic colo-
noscopy. For this study, controls were those found not to
have either CRC or adenomatous polyps. Subjects were
excluded from further analysis if excised polyps were
not recovered for histological analysis, or there was no
histological confirmation of polypoid lesions when expert
colonoscopists left presumed hyperplastic polyps in situ.
Cases
Patients who were subsequently found to have CRC at
their post-interview colonoscopy were included, in
addition patients with CRC diagnosed in the same time
frame but who did not have a pre-colonoscopy interview,
were indentified and underwent the same structured
interview after diagnosis. Post-diagnosis interviewing was
utilized for purely practical reasons: given the number of
procedures performed in our unit and the limited time
available to him, the part-time student interviewer had
insufficient time to interview all patients pre-colonoscopy.
As the majority of diagnostic colonoscopies have non-
malignant findings, it was necessary to use additional
methods to ensure an adequate sample size. Cases
interviewed post-diagnosis were on exactly the same
referral, diagnostic and treatment pathway as all other
cases and controls. All cases had histological confirmation
and were reviewed by a specialist GI pathologist (JS).
Ethics and research governance
All patients gave written informed consent and the study
was approved The Norfolk Research Ethics Committee
and the Norfolk and Norwich University Hospital Trust
Research Governance Committee.
Sample size and statistical analysis
An initial sample size of at least of 93 cases and 93
controls was planned: this had 80% power to detect a
50% relative risk reduction in CRC incidence in statin
users, assuming a statin use rate of 40% in controls.Statistical analyses were performed using SPSS version
16.0. The percentage of participants that had previously
used statins in each case group was compared against the
control group using a chi square statistic. The differences
between the groups were quantified using the calculated
odds ratios and 95% confidence intervals, with the
significance level set at p< 0.05. Further analysis was
performed, comparing the differences in duration, dose
and type of statin use between each case group and
the control group. The duration of statin use was
characterised into 3 categories: < 2 years, 2–5 years and
> 5 years. The statin dose category was dichotomised into
low dose (<40 mg simvastatin or equivalent /day) and
high dose (40 mg simvastatin or more or equivalent / day).
The type of statin used was separated into 2 categories,
simvastatin and other types of statin. For every statin
variable, each case group was compared against the
control group and odds ratios were calculated with 95%
confidence intervals compared to the reference never
used statin. All odds ratios were recalculated using
unconditional logistic regression, correcting for potential
confounding factors.
Results
Baseline characteristics and confounding factors
A total of 101 patients with CRC and 132 controls
were included in the study. Baseline characteristics and
demographic information for cases and controls are shown
in Table 1. There were significant differences (p= 0.05)
between the groups with regard to age, gender, current
weekly alcohol intake and type II diabetes. Table 2 shows
that previous aspirin and metformin use were both
significantly more common in controls than cases. There
were no significant differences between the cases and
controls with regard to the use of NSAIDs, calcium
channel blockers and other diabetes medications. The
multivariable regression analyses adjusted for all potential
confounding factors that showed statistically significant
differences between the groups. This included age, gender,
type II diabetes, weekly alcohol intake, and a history of
aspirin or metformin use. The indications for the
diagnostic colonoscopy are shown in Table 2. The
indications were typical of those in a United Kingdom
general hospital and were broadly similar between cases
and controls. Rectal bleeding was significantly more
commonly the indication in cancer patients and a change
in bowel habit was significantly more common in those
with a normal colonoscopy. Anaemia was found to be a
slightly, but not significantly, more common indication in
the control group.
Statins
There was a highly significant inverse association between
previous statin use of at least 6 months duration and a
Table 1 Baseline characteristic
Normal CRC
Number 132 101
Male (%) 61 (46.2) 63 (62.4)
Mean age, y (SD) 63.8 (12.2) 70.3 (10.2)
Type II diabetes (%) 26 (19.7) 8 (7.9)
Inflammatory bowel disease (%) 6 (4.5) 2 (2.0)
Family history* (%) 19 (14.4) 9 (8.9)
Smokers† (%) 55 (41.7) 44 (43.6)
Established coronary artery disease** 10 (8) 5 (5)
Mean smoking, pack years (SD) 8.3 (12.6) 8.4 (12.0)
Alcohol drinkers† (%) 89 (67.4) 76 (75.2)
Mean alcohol, units/week{ (SD) 6.5 (7.6) 8.5 (7.3)
BMI (SD) 27.1 (4.4) 26.2 (4.0)
HRT (% of women) 9 (12.7) 8 (21.1)
Mean parity (% of women) 2.25 (1.13) 2.58 (1.11)
Number of parous women (%) 65/71 (91.5) 37/38 (97.4)
Baseline characteristics of subjects included in the study.
Abbreviations: BMI = Body Mass Index; CRC = colorectal cancer, HRT=Hormone
Replacement Therapy.
* 1st degree relative with family history of CRC.
† Current or ex-smokers / alcohol drinkers.
** Coronary artery disease confirmed by angiography, cardiological opinion or
documented previous acute coronary syndrome or by-pass grafting.
{ Current weekly alcohol consumption.
Table 2 Indications for colonoscopy
Controls CRC cases p value
n (%) n (%)
Anaemia
Total 41 (31) 20 (20) 0.06
Statin users 22 4 0.01
Positive FOB screening
Total 26 (19) 13 (13) 0.17
Statin users 14 3 0.08
Rectal bleeding
Total 7 (5) 17 (16) 0.01
Statin users 3 5 0.60
Abnormal or equivocal imaging
Total 4 (3) 16 (16) 0.01
Statin users 1 2 0.60
Change in bowel habit
Total 41 (31) 25 (25) 0.29
Statin users 15 5 0.86
Abdominal pain
Total 13 (10) 8 (8) 0.62
Statin users 3 1 0.62
Palpable abdominal mass
Total 0 (0) 2 (2) 0.33
Statin users 0 0 -
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inverse association after adjustment for potential
confounders [OR=0.43 (0.25 – 0.80), p< 0.01]. There
were no patients in our cohort that had taken statins
previously but had subsequently stopped sometime before
having the colonoscopy. Thus statin exposure reflects a
continuous period prior to diagnosis. The majority of
statin use was prescribed in primary care for primary
prevention of coronary artery disease. There was no
difference in reported statin use between those cancer
patients interviewed pre-diagnostic colonoscopy (13/64,
20%) and those interviewed having already been informed
of their diagnosis (7/37, 18.9%) There was no obvious
difference in statin use between cancers of the rectum
(17%), left colon (20%) or right colon (22%), but numbers
in each group were too small to analyze separately.
Similarly there was no significant difference in statin use
when the stage of colorectal cancer was examined although
there was a trend for statin use to be less common in more
advanced disease (Dukes’ A 20%, B 21.5%, C 18% and
D 12.5%).
Duration
The protective effect of statins was greater with increased
time of exposure, as shown in Table 4, [<2 years:
OR=0.66 (0.21 – 1.69), p = 0.47], [2–5 years: OR=0.38
(0.14 – 1.01), p = 0.05], [>5 years: OR=0.18 (0.06 – 0.55),p< 0.01]. There was a significant linear trend for the
duration-response relationship between statin use and
CRC diagnosis [test for trend, x2 (1) = 26.8, p< 0.01].
Dose
There was a dose-dependent inverse relationship between
the dose of statin and CRC. The apparent protective
effect was greater at the higher statin dosage [OR=0.19
(0.07 – 0.47), p< 0.01] compared to the lower statin
dosage [OR=0.51 (0.21 – 1.24) p = 0.14] which did not
show a statistically significant difference. There was a
significant linear trend for the dose–response relationship
between statin use and CRC diagnosis [test for trend,
x2 (1) = 25.5, p< 0.01](Table 4).
Type of statin
Simvastatin was the most commonly used statin (75/106;
70.8%) the distribution of statin use was comparable
between cases and controls (Table 5). Statin use was
separately anaylsed as simvastatin and other statins. Can-
cer patients were significantly less likely to have used sim-
vastatin than controls [OR=0.43 (0.10 – 0.73), p< 0.01]
but although there was a similar numerical effect for other
statins, given the smaller numbers, this did not reach
statistical significance [OR=0.49 (0.13 – 1.13), p = 0.09].
Table 3 Use of other medications
Control CRC
n (%) n (%) OR (95% CI) p-value
aspirin 43 (32.6) 15 (14.9) 0.36 (0.18 -.70) < 0.01
NSAIDs 16 (12.1) 7 (6.9) 0.54 (0.20 -1.35) 0.19
CCMs* 12 (9.1) 7 (6.9) 0.75 (0.27 – 1.97) 0.55
metformin 18 (13.6) 5 (5.0) 0.33 (0.10 -0.89) 0.03
other diabetes 8 (6.1) 1 (1.0) 0.16 (0.03 – 1.19) 0.06
Use of medications in patients with colorectal cancer (CRC) and controls. Results expressed as odds ratio with 95% confidence intervals (95% CI). *calcium channel
modulators.
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Aspirin use was significantly protective against CRC
[uncorrected OR=0.36 (0.19 – 0.70) p< 0.01]. However,
when adjusted for statin use these protective effects
became non-significant against CRC [corrected OR=0.91
(0.39 – 2.11) p= 0.83]. However, after adjustment was
made for aspirin use, the protective effects of statins
remained significant against CRC [corrected OR=0.42
(0.12 – 0.71) p< 0.01]. The combination of aspirin and
statin was associated with a numerically, but statistically
insignificantly, greater protective effect against CRC
than either statin or aspirin alone [corrected OR 0.15
(0.04 – 0.47)].
Discussion
In this case–control study, statin use was associated with a
significantly reduced incidence of CRC. These findings
remained after adjustment for potential confounding
factors. There was a significant duration- and dose–
response relationship with greater statin exposure offering
more protection against CRC. The use of simvastatin was
significantly protective but although exactly the same
pattern was seen with the other statins, the numbers were
too small to reach conventional statistical significance.Table 4 Statins and CRC
Controls (%) CRC (%)
any previous use 68/132 (51.5) 20/101 (19.8)
Duration
< 2 years 14 (11%) 8 (8)
2 – 5 years 23 (17) 7 (7)
> 5 years 31 (24) 5 (5)
Dose
< 40 mg/day 28 (21) 12 (12)
= or> 40 mg/day 40 (30) 8 (8)
statin type
simvastatin 49 (37) 14 (14)
other 19 (14) 6 (6)
Use of statins in patients with colorectal cancer (CRC) and controls. Results expresse
gender, type II diabetes, aspirin use, metformin use and weekly alcohol intake and cThese data support a causal relationship between statin
exposure and reduced risk of colorectal neoplasia.
These results are consistent with previous studies and a
meta-analysis suggesting a protective effect [8-12], and the
protective effective against CRC seen in the original
randomized trials of statin use in cardiovascular disease
[18,28], although the strength of the apparently protective
effect is rather greater in our study than several other
positive studies. Not all case–control and cohort studies
have shown consistent results and no association with
reduced risk has been reported [20,22-25]. There may be
several reasons for the inconsistencies between studies,
including different populations with different underlying
CRC risk, different control groups, and inadequate length
of follow up in cohort studies or insufficient statin
exposure to detect a protective effect (some studies includ-
ing all patients with statin exposure of only 3 months).
There is biological plausibility to our data: we detected
both time- and dose-dependent effects against CRC
development and experimental studies are supportive of
CRC-protective effects of statins. In addition to in vitro
cell line studies, statins have been shown to reduce polyp
formation in Min−/− mouse models [29] and pre-neoplastic
and neoplastic lesions in animal models [30,31]. A singleOdds ratios (95% CI)
P-value Unadjusted Adjusted*
< 0.01 0.23 (0.13 – 0.42) 0.43 (0.25 – 0.80)
0.47 0.73 (0.56 – 3.43) 0.66 (0.21 – 1.69)
0.05 0.35 (0.15 – 0.86) 0.38 (0.14 – 1.01)
< 0.01 0.17 (0.063 – 0.454) 0.18 (0.06 – 0.55)
0.14 0.50 (0.24 – 1.04) 0.51 (0.21 – 1.24)
< 0.01 0.20 (0.09 – 0.45) 0.19 (0.07 – 0.47)
< 0.01 0.27 (0.14 – 0.53) 0.43 (0.10 – 0.73)
0.09 0.38 (0.14 – 0.98) 0.49 (0.13 – 1.13)
d as odds ratio with 95% confidence intervals (95% CI). *Adjusted for age,
ompared to never used statins.
Table 5 Use of statins
Control (%) CRC (%)
simvastatin 49 (37.1) 14 (13.0)
atorvastatin 7 (5.3) 3 (3.0)
pravastatin 4 (3.0) 1 (1.0)
rosuvastatin 8 (6.0) 2 (20.0)
Total 68 (51.5) 20 (19.8)
Use of different statins in patients with colorectal cancer (CRC) and controls.
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reduced rate of post-polypectomy adenomatous polyp
formation [32], although another study with shorter follow
up failed to detect any protective effect of statins against
polyp recurrence [33].
More recent studies have suggested that biological
differences may underlie some of the variability in the
apparent effects of statins. Upregulation of HMG-CoA
has been reported in CRCs but one study has shown this
to be more marked in left sided cancers [15]. Similarly
HMG-CoA genotype seems to influence the protective
effect of statins: a higher activity allele was associated
with a protective effect, whereas a significant protective
effects was not associated with a lower activity allele
[11]. The polyp-cancer sequence is estimated to take
10–15 years and it is not clear, where along this
sequence the effect of statins may be most noticeable [34].
Experimental studies have shown that statins may become
less effective in cell lines as more genetic and hence
functional changes downstream of the putative cellular
effect of statins accumulate [35,36]. If, for example, the
effect of stains is more prominent at stages of polyp-
development or progression, then the average age of
initiation of statin therapy in any population is likely to
contribute to differing effects of statins on CRC incidence
between studies.
The main specific strengths of our study are the compre-
hensive drug history available and the fact that all patients
underwent diagnostic colonoscopy. Many previous studies
have used prescribing records and although these studies
have many advantages, they may misreport actual drug
exposure as not all prescribed medication is actually
consumed. In addition in the United Kingdom aspirin,
ibuprofen, diclofenac and simvastatin are available to
purchase without prescription, thus we feel our records of
drug exposure are both accurate and comprehensive.
Asymptomatic colon cancer is not uncommon and our
use of a control group, who all underwent colonoscopy
will have minimized bias due to misdiagnosis which is a
problem in uninvestigated cohorts. There are data from
the USA showing that patients with co-morbidity undergo
more frequent screening colonoscopies [37]. We only
included cases and controls having their first ever
diagnostic colonoscopy, so removing any potential biasfrom repeated colonoscopy or previous polyp removal. A
potential disadvantage of our design studying symptomatic
patients attending for diagnostic colonoscopy is that the
control group may exhibit more health-seeking behavior
and be more health conscious and hence introduce bias.
However all had genuine symptoms for which colonos-
copy would be indicated and as all were provided under
the United Kingdom National Health Service, no direct
financial or insurance incentives will have influenced
decisions regarding colonoscopy. An ideal study would
examine statin use in cases and controls from asymptom-
atic patients invited for colonoscopic colon cancer
screening, rather than symptomatic patients; however this
would not be possible as the United Kingdom national
screening programme is based on initial faecal occult
blood screening, followed by colonoscopy only in those
testing positive. Interestingly the association of reduced
CRC incidence in statin uses was also seen in the sub-
group of patients that presented via the national screening
program with positive faecal occult bloods, although the
overall number of cases in this group was too small to
draw definite conclusions (statin use: controls 14/26, 53%,
cases 3/13, 23% OR 0.37 (0.06 – 1.17)).
The issue of bias inherent to the control group affecting
the results must always be considered in case–control and
cohort studies, in particular the possibility that statin users
are generally more health-conscious and this explains their
lower CRC risk. As with previous studies in this field,
we cannot exclude this completely but we feel this is an
unlikely explanation of the findings. It is possible that
statin-users may have had more specific dietetic input and
this lead to a positive change in diet which influenced
cancer risk. The majority of statin prescribing was by the
patients’ primary care physician for the primary prevention
of vascular disease and as such was not governed by any
specific protocol and both patient and clinician perception
are likely to have influence the use of statins. The control
group is comparable to a standard low-moderate CRC
risk cohort undergoing diagnostic colonoscopy for any
indication in the UK and comparable to the age-matched
population as a whole. In terms of smoking, alcohol intake,
BMI and type 2 diabetes as markers of health-related
behaviors, the control group did not appear to be
especially healthier than the cases and the effect of statins
persisted after correction for all known confounding
variables. The risk of colonic neoplasia is probably
increased in both diabetes mellitus and established
coronary artery disease [6,38], and this would have been
expected to reduce any effects of statins observed in our
study. Chronic statin use is associated with a very low
incidence of gastrointestinal side effects and so it seems
unlikely that statins are over-represented in the control
group because they were responsible for symptoms
initiating the referral for colonoscopy [39]. It could be
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gastrointestinal bleeding and anaemia, this could have led
to over-representation of aspirin in the control group and
indeed there was a slightly higher number of controls in
which anaemia was the presenting condition. Whilst this
is possible, our study showed a protective effect of aspirin
entirely consistent with other studies that used different
control groups [25], and the effect of statins persisted after
correction for aspirin use. We also showed an apparent
protective effect of metformin against CRC, again
consistent with previous studies, suggesting our results
have external validity [40].
This study did have limitations, some of which were
inherent with the case control study design. Despite this
study being sufficiently powered to produce statistically
significant results, this was a relatively small cohort
compared to some similar case control studies. Data
collection was cross referenced using patient interviews
and clinical notes but recall bias may have caused
inaccuracy and difficulty in determining the extent of
exposure to medications, although as most subjects were
interviewed in the same situation pre-colonoscopy, this is
unlikely to unduly influence cases or controls. Data were
collected for many potential confounding factors that had
been identified from the literature but other uncontrolled
confounders could have affected the results. We did not
attempt to address the issues regarding diet and cancer
risk and further studies in the area would benefit from
including this. Although we utilized both pre- and post-
cancer diagnosis interviews to establish statin exposure,
we do not feel this introduced any bias of recall. All drugs
exposures were accurately cross-referenced to medical
records (including pre-colonoscopy medical notes), statins
are characteristically long-term therapies and once started
are very rarely stopped and although patients were
informed we were interested in risk factors for their
diseases, they were unaware of which particular factors.
Our results show no difference in statin use between those
interviewed pre- and post-colonoscopy. However the issue
of residual confounding by other unrecognized factors
must still be considered. Similarly, although adequately
powered for our pre-designed end-point, the relatively
small size of our study may have contributed to the
relatively large protective association that we have
described.
Investigating the effect of statins and aspirin produced
interesting findings. The use of statins or aspirin produced
a significant protective effect, although statin use was
considerably more prevalent in this population. There was
a suggestion that the combination of aspirin and statin
was associated with a lower incidence of CRC, and in vitro
cell line and mouse models studies would support a
beneficial interaction between statins and cyclo-oxygenase
inhibitors [14,41-44].Conclusion
In conclusion, our case–control study shows that statin
use was associated with a lower incidence of colorectal
cancer and this effect was associated with a significant
dose and duration response. Statins may have a protective
effect against the development of CRC. We recommend
that future studies examining chemoprevention and
causation correct for statin exposure and that as statins do
seem to have some promise as chemopreventative agents,
further studies examining the effects of statins are
required, these should examine the interactions with other
agents as well as population or cancer variables that may
influence statin response.
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